ArticleJournal for immunotherapy of cancer2020

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.

Anna Minchom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.